Dr Shallis on the Utility of Luspatercept in the ELEMENT-MDS Trial in MDS

Sdílet
Vložit
  • čas přidán 9. 09. 2024
  • Rory Shallis, MD, assistant professor, medicine (hematology), Yale School of Medicine, Yale New Haven Health, discusses the utility of luspatercept-aamt (Reblozyl) as evaluated in the phase 3 ELEMENT-MDS trial (NCT05949684) for patients with myelodysplastic syndrome (MDS).
    Website: www.onclive.com
    Twitter: / onclive
    Facebook: / onclive
    LinkedIn: / onclive

Komentáře •